Price to Earnings (P/E)
since 2018
Calculation
Moderna Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss) attributable to common stockholders1 (in millions) | ÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | — | = | 96.46 | ÷ | -12.34 | -12.34 | = | -4,714 | ÷ | 382,073,208 | |
| Feb 24, 2023 | 6.43 | = | 139.26 | ÷ | 21.64 | 21.64 | = | 8,362 | ÷ | 386,339,594 | |
| Feb 25, 2022 | 5.00 | = | 151.33 | ÷ | 30.29 | 30.29 | = | 12,202 | ÷ | 402,872,986 | |
| Feb 26, 2021 | — | = | 154.81 | ÷ | -1.87 | -1.87 | = | -747 | ÷ | 399,769,582 | |
| Feb 27, 2020 | — | = | 26.16 | ÷ | -1.39 | -1.39 | = | -514 | ÷ | 368,642,548 | |
| Mar 13, 2019 | — | = | 19.97 | ÷ | -1.22 | -1.22 | = | -402 | ÷ | 329,000,469 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Moderna Inc. Annual Report.
Comparison to Competitors
Moderna Inc., P/E, long-term trends, comparison to competitors
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | — | 63.84 | 23.14 | 12.27 | 39.09 | 135.24 | 16.17 | 10.73 | 893.99 | 73.42 | 25.99 | 35.65 |
| Feb 24, 2023 | 6.43 | 22.62 | 19.56 | 23.97 | 25.65 | 50.08 | 22.68 | 22.97 | 19.21 | 7.58 | 19.68 | 30.55 |
| Feb 25, 2022 | 5.00 | 22.07 | 21.05 | 20.92 | 29.94 | 40.66 | 12.36 | 20.93 | 14.78 | 11.76 | 8.37 | 27.35 |
| Feb 26, 2021 | — | 40.17 | 18.82 | — | 44.49 | 31.95 | 641.48 | 28.92 | 26.72 | 19.62 | 15.09 | 27.89 |
| Feb 27, 2020 | — | 17.82 | 17.07 | 41.99 | 38.34 | 16.19 | 16.45 | 25.99 | 20.60 | 11.63 | 19.86 | 33.36 |
| Mar 13, 2019 | — | 20.60 | 14.01 | 16.81 | 29.77 | 39.13 | 15.26 | 23.74 | 33.46 | 21.58 | 18.17 | 35.19 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Moderna Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 23, 2024 | — | 32.90 |
| Feb 24, 2023 | 6.43 | 20.15 |
| Feb 25, 2022 | 5.00 | 19.12 |
| Feb 26, 2021 | — | 35.63 |
| Feb 27, 2020 | — | 20.58 |
| Mar 13, 2019 | — | 22.89 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Industry (Health Care)
Moderna Inc., P/E, long-term trends, comparison to industry (health care)
| Moderna Inc. | Health Care | |
|---|---|---|
| Feb 23, 2024 | — | 28.80 |
| Feb 24, 2023 | 6.43 | 330,078.16 |
| Feb 25, 2022 | 5.00 | 20.96 |
| Feb 26, 2021 | — | 28.69 |
| Feb 27, 2020 | — | 20.94 |
| Mar 13, 2019 | — | 25.33 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).